Sygnis

Sygnis Receivables

The Accounts Receivable of Sygnis (SYG.WA) as of Nov 12, 2026 is 5.57 M PLN. In the previous year, Accounts Receivable was 536,400.00 PLN — a change of 938.63% (higher).

Receivables

5.57 MPLN

YoY

938.63%

Last updated:

Accounts Receivable of Sygnis is 2025 5.57 M PLN. Accounts Receivable of Sygnis was 2024 536,400.00 PLN. It decreases by 938.63% higher compared to the previous year.

The Sygnis Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
41,800.00 PLN
Jan 1, 2019
165,200.00 PLN
Jan 1, 2020
100,100.00 PLN
Jan 1, 2021
2.59 M PLN
Jan 1, 2022
2.31 M PLN
Jan 1, 2023
730,300.00 PLN
Jan 1, 2024
536,400.00 PLN
Jan 1, 2025
5.57 M PLN
The Sygnis Receivables history
YEARReceivablesYoY
5.57 MPLN+938.63%
536,400.00PLN-26.55%
730,300.00PLN-68.34%
2.31 MPLN-10.96%
2.59 MPLN+2,488.41%
100,100.00PLN-39.41%
165,200.00PLN+295.22%
41,800.00PLN+828.89%
4,500.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sygnis Stock analysis

What does Sygnis do? Sygnis SA generates revenue through its research and development services across four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence focuses on bioprinting organs to prevent transplant shortages and creating bionic models for drug testing. Nanotechnology applies photoelectron spectroscopy and atomic force microscopy solutions to consumer products. Power Engineering develops energy storage methods for renewable energy sources. New Incremental Technologies specializes in 3D printing solutions. The company collaborates with over 85 specialists including physicists, mechatronics, chemists, engineers, designers, and sociologists to execute multiple projects. Clients for Sygnis SA's services include organizations requiring advanced research in bioprinting, nanotechnology applications, energy storage, and 3D printing solutions. The firm serves sectors such as healthcare, technology, and renewable energy through its specialized R&D segments. Projects are executed by its team of 85 specialists working across the four business areas. Sygnis SA's revenue streams are derived from contracts with clients seeking innovative R&D in organ bioprinting, bionic drug testing models, photoelectron spectroscopy applications, energy storage systems, and 3D printing technologies. The company's business model relies on delivering specialized research services to clients across healthcare, technology, and renewable energy sectors through its four distinct R&D segments. Sygnis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sygnis stock

Accounts Receivable of Sygnis is 5.57 M PLN in 2025.

Accounts Receivable of Sygnis changed from 536,400.00 PLN to 5.57 M PLN, representing a 938.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Sygnis since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Sygnis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Sygnis

All Key Metrics — Sygnis